(Olmesartan and Valsartan Anti-atherosclerosis Trial in Patients with Mild-Hypertension: Using Three-dimensional serial IVUS)Study
- Conditions
- stable angina pectoris with mild hypertension
- Registration Number
- JPRN-C000000028
- Lead Sponsor
- The Department of Cardiology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
(non-lesion related items) 1)Patients with acute coronary syndrome 2)Previous history of Q myocardial infarction within 4 weeks before the randomization 3)Low left ventricular(LV) function(LV ejection fraction < 45%) 4)Patients with renal failure(serum creatinine > 3.0mg) 5)Patients who are treated with angiotensin converting enzyme inhibitor or receptor blocker, or aldosterone receptor blocker at randomization (lesion related items) 1)chronic total coronary artery occlusion 2)lesions on bypass grafts 3)unsuccessful stent implantation (stenosis > 50% after PCI) 4)lesions with prior atheroablative procedures before stent implantation 5)lesions implanted with multiple stents 6)left main trunk lesions 7)lesions on small vessels(reference diameter < 2.0 mm) 8)calcified lesions, which preclude accurate quantification of IVUS imaging
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method nominal changes in % plaque volumes by three-dimensional intravascular ultrasound at 6-8 months follow-up after percutaneous coronary intervention
- Secondary Outcome Measures
Name Time Method (IMT) change from baseline in mean IMT after 6-8 months (E/A) change from baseline in E/A after 6-8 months by echocardiography (laboratory test) hs-CRP, adiponectine, aldosterone, renin, oxLDL, HOMA-R, TC, TG, LDL-C, HDL-C, etc